The Latest Antibody Industry Statistics Explained
The global antibody market was valued at $220 billion in 2019 and is set to reach $341.1 billion by 2025.
This statistic indicates that the global antibody market, which encompasses the production and sale of antibodies for various applications such as diagnostics and therapeutics, was valued at $220 billion in 2019. The projected growth of this market is significant, with an expected increase to $341.1 billion by the year 2025. This indicates a strong upward trend in the demand for antibodies and suggests a promising outlook for the industry. Factors such as technological advancements, increased investment in research and development, and the rising prevalence of chronic diseases are likely driving this growth in the antibody market over the forecasted period.
Around 60% of the sales in the antibody market originates from the therapeutic antibodies segment.
The statistic ‘Around 60% of the sales in the antibody market originates from the therapeutic antibodies segment’ indicates that a significant majority of the revenue generated in the overall antibody market comes from therapeutic antibodies specifically. This implies that the demand for antibodies used in therapeutic applications, such as treating diseases or disorders, is a major driving force behind the market’s sales. The statistic suggests that therapeutic antibodies hold a dominant market share compared to other segments within the antibody market, highlighting the importance and popularity of these products in the healthcare industry.
Monoclonal antibodies segment dominated with 75.5% share of the global antibody market in 2019.
The statistic ‘Monoclonal antibodies segment dominated with 75.5% share of the global antibody market in 2019’ indicates that in 2019, monoclonal antibodies accounted for the majority of sales in the global antibody market, with a market share of 75.5%. Monoclonal antibodies are a type of protein produced in a laboratory that can mimic the immune system’s ability to fight off harmful pathogens. This dominance suggests that the demand for monoclonal antibodies was high, likely due to their effectiveness in treating a variety of diseases, such as cancer, autoimmune disorders, and infectious diseases. The strong market presence of monoclonal antibodies highlights their importance and widespread adoption in the medical and pharmaceutical industries.
The largest end-use market for antibodies is oncology, which claimed over 52.7% of the total revenues in 2019.
The statistic indicates that in 2019, the field of oncology represented the largest end-use market for antibodies, accounting for 52.7% of the total revenues generated by the antibody industry. This data suggests that a significant portion of the demand for antibodies comes from applications within the field of oncology, which encompasses the diagnosis, treatment, and research of cancer. The high percentage of revenues attributed to oncology demonstrates the importance and widespread use of antibodies in the detection and treatment of cancerous diseases, reflecting the crucial role that antibodies play in advancing oncology research and clinical practices.
In 2016, biotech became the biggest sector for private funding, receiving nearly 40% of all funds.
The statistic indicates that in the year 2016, the biotechnology sector secured the largest share of private funding compared to other industries, with approximately 40% of total funds invested. This highlights a strong investor interest and confidence in the biotech industry during that period. The significant allocation of funds towards biotechnology suggests that investors recognized the potential for growth, innovation, and future returns within this sector. This statistic may also reflect advancements in biotechnology research and development, as well as the perceived opportunity for breakthrough discoveries and technological advancements in areas such as healthcare, pharmaceuticals, and agriculture.
By 2023, the biopharmaceutical industry is forecast to spend over $10 billion in aggregate on the clinical development of monoclonal antibodies.
The statistic indicates that by the year 2023, the biopharmaceutical industry is projected to invest a total of over $10 billion specifically on the clinical development of monoclonal antibodies. Monoclonal antibodies are a type of biopharmaceutical drug that are engineered to target specific proteins in the body, and they have become increasingly important in the treatment of various diseases such as cancer, autoimmune disorders, and infectious diseases. This significant level of investment reflects the industry’s commitment to advancing the development of monoclonal antibodies and highlights the growing importance of this therapeutic approach in modern healthcare. The substantial financial resources being allocated towards clinical research and development in this area suggest a strong focus on innovation and the potential for significant advancements in the field of biopharmaceuticals.
The antibody production market in the Asia Pacific region is expected to grow at a CAGR of 13.2% from 2020 to 2027.
This statistic indicates that the market for antibody production in the Asia Pacific region is projected to experience a Compound Annual Growth Rate (CAGR) of 13.2% from the year 2020 to 2027. The CAGR of 13.2% represents the average annual rate at which the market size is expected to increase over the specified time period. This growth rate highlights a substantial and continuous expansion in the demand for antibody production products and services within the Asia Pacific region over the forecasted years, suggesting a favorable market outlook for stakeholders involved in this sector.
North America dominated the global antibody market in 2019 with a share of 45.4%.
The statistic that North America dominated the global antibody market in 2019 with a share of 45.4% indicates that nearly half of the total antibody market revenue worldwide originated from North America alone. This dominance highlights the significant presence and influence of North American companies, research institutions, and healthcare providers in the development, manufacturing, and distribution of antibodies. The region’s strong market position suggests a high level of innovation, expertise, and investment in antibody-related technologies and products, making it a pivotal player in the global biotechnology and pharmaceutical industries.
The primary antibodies segment dominated the global market with a revenue share of 64.3% in 2019.
The statistic indicates that in 2019, the primary antibodies segment significantly led the global market in terms of revenue, accounting for 64.3% of the total market share. This suggests that primary antibodies were the most popular and sought-after category within the market, indicating a strong demand for these types of antibodies. Companies and researchers producing and utilizing primary antibodies likely experienced success and growth compared to other segments in the market during that period. This statistic highlights the importance and prominence of primary antibodies in the global market landscape in 2019.
The reagents and kits market segment is projected to expand at the fastest CAGR (compound annual growth rate) of 6.3% from 2020 to 2027.
The statement indicates that the reagents and kits market segment is expected to have the highest growth rate among all market segments, with a compound annual growth rate (CAGR) of 6.3% from the year 2020 to 2027. This implies that the demand for reagents and kits within this segment is predicted to increase significantly over the specified time frame. A higher growth rate suggests expanding opportunities for businesses within this market segment, indicating potential profitability and a favorable business environment. This information is valuable for investors, businesses, and stakeholders who can strategize and capitalize on this projected growth to maximize their returns.
As of 2020, there are more than 570 antibody-based therapeutics undergoing clinical development worldwide.
The statistic “As of 2020, there are more than 570 antibody-based therapeutics undergoing clinical development worldwide” indicates a significant and growing trend in the field of medical research and development. Antibody-based therapeutics, which involve the use of antibodies to target specific molecules in the body for therapeutic purposes, have gained popularity due to their potential for targeted treatment and reduced side effects. The fact that over 570 of these therapies are in clinical trials globally demonstrates the increasing interest and investment in this type of treatment approach, highlighting the potential for future advancements in healthcare and the treatment of various diseases.
The use of Antibody-Drug Conjugates (ADCs) has increased 6.5-fold in clinical trials between 2003 and 2021.
The statistic indicates that the utilization of Antibody-Drug Conjugates (ADCs) in clinical trials has risen significantly over the time period from 2003 to 2021, specifically increasing by 6.5 times. This substantial 6.5-fold increase suggests a growing interest and investment in the development and testing of ADCs as a potential treatment modality. The uptick in clinical trials involving ADCs may be indicative of the expanding research focus on leveraging the specificity of antibodies to deliver cytotoxic drugs to targeted cells, thereby enhancing the effectiveness and reducing the side effects of chemotherapy in cancer treatment. This remarkable increase in the use of ADCs underscores their potential as a promising therapeutic approach in modern medicine.
According to the World Health Organization (WHO), of the top 10 bestselling drugs in 2019, seven were monoclonal antibodies.
The statistic suggests that monoclonal antibodies were prevalent among the top-selling drugs in 2019. Monoclonal antibodies are a type of targeted therapy that can be used to treat a variety of conditions, including cancer, autoimmune disorders, and infectious diseases. The fact that seven out of the top 10 bestselling drugs were monoclonal antibodies indicates their significant impact and widespread use in healthcare. This trend may reflect advancements in biotechnology and personalized medicine, as monoclonal antibodies can be tailored to specific targets in the body, allowing for more precise and effective treatments for patients.
The US FDA approved 25 new antibody therapeutics in 2020.
The statistic “The US FDA approved 25 new antibody therapeutics in 2020” highlights a significant increase in the number of antibody-based drugs that were granted approval by the US Food and Drug Administration (FDA) during the year 2020. Antibody therapeutics are a type of medication that uses antibodies to target specific molecules in the body, often to treat diseases such as cancer, autoimmune disorders, and infectious diseases. The approval of 25 new antibody therapeutics in a single year reflects both the growing importance of these treatments in modern medicine and the continuous efforts of the pharmaceutical industry to develop innovative therapies to address various health challenges.
Roughly 10% of pharmaceutical companies are investing in antibody technologies.
The statistic indicates that approximately 10% of pharmaceutical companies are allocating resources towards antibody technologies, which are specialized therapies that use antibodies to target specific molecules or cells in the body. This investment suggests a growing interest in the development and utilization of antibodies for medical purposes within the pharmaceutical industry. Companies investing in antibody technologies may be focusing on developing new treatments for various diseases or improving existing therapies, as antibodies have shown promise in areas such as oncology, immunology, and infectious diseases. The statistic highlights a trend towards the adoption of advanced biotechnologies in drug discovery and development efforts among a subset of pharmaceutical companies.
Antibody therapeutics accounted for around 15-20% of the total pharmaceutical market in 2020.
This statistic indicates that antibody therapeutics, which are a type of biopharmaceutical drug designed to target specific molecules in the body, comprised approximately 15-20% of the overall pharmaceutical market in 2020. This suggests that antibody-based treatments are gaining significant traction and recognition within the healthcare industry, likely due to their effectiveness in treating a variety of diseases such as cancer, autoimmune disorders, and infectious diseases. The growth in the market share of antibody therapeutics reflects the increasing interest and investment in biologics as a key area of pharmaceutical innovation, potentially driving further research and development in this sector.
There were 338 US FDA-approved therapeutic antibodies to treat diseases including cancer and immune disorders on the market as of 2021.
The statistic that there were 338 US FDA-approved therapeutic antibodies to treat diseases such as cancer and immune disorders as of 2021 indicates the significant growth and importance of antibody-based therapies in the field of medicine. Therapeutic antibodies have become a crucial tool in the treatment of various diseases by targeting specific molecules involved in disease processes. The approval of a large number of antibodies highlights their effectiveness and specificity in treating conditions like cancer and immune disorders, offering patients more targeted and personalized treatment options. This statistic reflects the continuous advancements in biotechnology and the increasing trend towards precision medicine in healthcare.
Antibody production technologies have evolved substantially over the past decade, with recombinant production emerging as the favored method in the biopharmaceutical industry.
The statistic indicates that there has been significant advancement in the technologies used to produce antibodies over the last ten years, with recombinant production being widely adopted by the biopharmaceutical industry. Recombinant production involves the use of genetically engineered cells to produce specific antibodies, offering numerous advantages such as increased efficiency, scalability, and customization compared to traditional methods. This shift towards recombinant production suggests that the industry recognizes the potential benefits and is adapting to leverage these modern technologies to enhance antibody production processes for various therapeutic and diagnostic applications.
Nearly 50 new monoclonal antibodies are introduced into phase 1 clinical trials each year.
The statistic that nearly 50 new monoclonal antibodies are introduced into phase 1 clinical trials each year indicates a consistent level of innovation and research in the field of biopharmaceuticals. Monoclonal antibodies are a type of targeted therapy that have shown promise in treating various diseases, including cancer and autoimmune disorders. The fact that a substantial number of these antibodies are entering phase 1 clinical trials suggests ongoing efforts to develop new and potentially more effective treatments. Phase 1 clinical trials are the first stage of testing in humans and focus on safety and dosing, indicating that these monoclonal antibodies are progressing through the research and development pipeline towards potential approval for clinical use. This statistic highlights a trend of significant investment and advancement in the field of monoclonal antibody therapy.
References
0. – https://www.www.cytivalifesciences.com
1. – https://www.www.ncbi.nlm.nih.gov
2. – https://www.www.who.int
3. – https://www.bionomous.ch
4. – https://www.clarivate.com
5. – https://www.jamanetwork.com
6. – https://www.www.globenewswire.com
7. – https://www.www.antibodysociety.org
8. – https://www.home.kpmg
9. – https://www.www.grandviewresearch.com
10. – https://www.www.pharmasalmanac.com
